Bicalutamide
- Generic Name
- Bicalutamide
- Brand Names
- Casodex
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14F4N2O4S
- CAS Number
- 90357-06-5
- Unique Ingredient Identifier
- A0Z3NAU9DP
- Background
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
- Indication
Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.
- Associated Conditions
- Metastatic stage D2 Prostatic carcinoma
- Associated Therapies
- -
Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
- Conditions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Virginia Mason Hospital/Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT00348998
- Locations
- 🇺🇸
Benaroya Research Institute at Virginia Mason Medical Center, Seattle, Washington, United States
CMAB vs IMAB in Metastatic Prostate Cancer
- Conditions
- First Posted Date
- 2005-11-18
- Last Posted Date
- 2007-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT00255268
- Locations
- 🇲🇽
Research Site, Mexico City, Mexico
Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer
- Conditions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT00244920
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
- Conditions
- Interventions
- First Posted Date
- 2005-10-24
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Schiffler Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00243646
- Locations
- 🇺🇸
Seattle Prostate Institute, Seattle, Washington, United States
🇺🇸Groupe Health Cooperative, Veterans Adminstration Hospital and University of Washington, Seattle, Washington, United States
🇺🇸Schiffler Cancer Center, Wheeling, West Virginia, United States
Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT00233610
- Locations
- 🇮🇹
Research Site, Roma, Italy
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 112
- Registration Number
- NCT00170157
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 62
- Registration Number
- NCT00165399
- Locations
- 🇺🇸
University of Massachusetts Memorial Medical Center-University Campus, Worcester, Massachusetts, United States
🇺🇸Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-04-19
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00108732
- Locations
- 🇺🇸
Baptist Cancer Institute, Jacksonville, Florida, United States
🇺🇸Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 20
- Registration Number
- NCT00099086
Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]
- First Posted Date
- 2004-10-18
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT00094328
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.